Department of Neurology and Wilhelm Sander-NeuroOncology Unit, Regensburg University Hospital, Franz-Josef-Strauss-Allee 11, 93053, Regensburg, Germany.
Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Spitalstrasse 26, 4031, Basel, Switzerland.
Eur J Epidemiol. 2016 Sep;31(9):947-52. doi: 10.1007/s10654-016-0145-7. Epub 2016 Apr 4.
Statins have been reported to decrease the incidence of cancer, but the risk of glioma among statin users has been investigated in only two prior observational studies, both of them suggesting a modest protective effect of statins. We conducted a matched case-control study using data from the UK-based Clinical Practice Research Datalink to analyse use of statins among 2469 cases with glioma and 24,690 controls. We performed conditional logistic regression analysis to calculate relative risks, estimated as odds ratios (ORs) with 95 % confidence intervals (CIs) adjusting for multiple confounding factors. As compared with non-use of statins, use of statins was not associated with risk of glioma (OR for ≥90 prescriptions=0.75; 95 % CI 0.48-1.17). Our findings do not support previous sparse evidence of a possible inverse association between statin use and glioma risk.
他汀类药物已被报道可降低癌症的发病率,但仅有两项先前的观察性研究调查了他汀类药物使用者中胶质瘤的风险,这两项研究均表明他汀类药物具有适度的保护作用。我们使用来自英国临床实践研究数据库的数据开展了一项匹配病例对照研究,以分析 2469 例胶质瘤病例和 24690 例对照者中他汀类药物的使用情况。我们通过条件逻辑回归分析计算相对风险,使用比值比(OR)及其 95%置信区间(CI)来估计,调整了多种混杂因素。与不使用他汀类药物相比,使用他汀类药物与胶质瘤风险无关(≥90 个处方的 OR=0.75;95%CI 0.48-1.17)。我们的研究结果不支持他汀类药物使用与胶质瘤风险之间可能存在负相关的先前零星证据。